On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Zenosense, Inc. (ZENO) Reports Successful Quantitative Testing Results for MIDS Cardiac™ Technology

  • Cardiovascular diseases are costing the U.S. $1 billion per day in medical fees and productivity losses
  • The number of heart attacks is increasing on an annual basis, highlighting the importance of early detection technology
  • Zenosense is developing a handheld device that could significantly lower cardiovascular-related death rate and associated medical costs by enabling swift, accurate diagnostic

Health care technology company Zenosense, Inc. (OTC: ZENO) has announced the successful completion of a second round of testing for its MIDS Cardiac™ detection technology – a handheld system designed to rapidly test for certain cardiac biomarkers at the point of care, saving medical personnel crucial time in time-sensitive situations.

Diagnostic devices play a major role in the growth and expansion of the medical technology sector (http://ibn.fm/13GIN). Under development by the company’s MIDS Medical Limited (“MML”) joint venture based at the prestigious Sci-Tech Daresbury campus in the United Kingdom, MIDS Cardiac is a patented handheld POC technology for the detection of heart attack. It is designed to help medical staff rapidly diagnose heart attack at an early stage and improve treatment and patient outcomes. Through the early detection of certain cardiac event biomarkers, MIDS Cardiac is expected to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain suspected as symptomatic of a heart attack.

In a news release announcing breakthrough quantitative testing results (http://ibn.fm/UMiEP), Zenosense reported revisions and improvements to the core MIDS technology’s sensor electronics, materially improving on previous electronics testing results announced in 2017. In addition, the sensitivity of the MIDS technology electronics has been nearly doubled.

In 2017, the first next generation troponin assay for the early detection of heart attacks was approved by the FDA for use in the U.S. High sensitivity (HS) troponin assays have long been in use in the rest of the world. Such assays have to be performed on state of the art lab analyzers that are incredibly expensive. The aim of Zenosense is to deliver a handheld device capable of detecting and measuring diagnostic assay beads to support HS troponin assays in the emergency room and clinical settings. Such handheld devices will also prove to be invaluable for the work of paramedics on the go. As a part of the 2018 testing, Zenosense has managed to improve MIDS technology electronics and carry out independent third-party verification of bead numbers.

In a news release, MML managing director and Chief Scientific Officer Dr. Nasser Djennati noted that the project is hugely challenging. “The results of this second round of testing are quite extraordinary, as magnetic detection at this level for this application is unheard of,” he added. The next key step in the development of the technology will be testing microfluidic detection on the revised electronic platform.

Heart disease is a leading cause of death in the Western world. Approximately 610,000 people in the U.S. die of heart disease every single year (http://ibn.fm/4mYXf) – one in four deaths in the country. Nearly 735,000 Americans have a heart attack each year. Cardiovascular disease, including heart attacks and strokes, costs America nearly $1 billion a day in medical fees and lost productivity, according to a CDC Foundation study (http://ibn.fm/Ag7cE). Annual medical costs related with cardiovascular diseases are likely to reach $818 billion, while productivity losses could go over $275 billion by 2030, the same study shows.

According to the World Health Organization, early detection is one of the most important prerequisites for the successful management of cardiovascular problems.

With detection equal or superior to state of the art laboratory analyzers and advanced portability allowing it to be used at point of care, including in an emergency setting, MIDS Cardiac™ would be an absolute game changer which could help save lives and money by enabling a swift diagnosis with previously unheard of accuracy at the point of care (http://ibn.fm/GxOTH).

For more information, visit the company’s website at www.Zenosense.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered